UNC3230 is primarily utilized in research settings as a potent and selective inhibitor of the protein kinase VRK1 (Vaccinia-Related Kinase 1). Its application is significant in studying the role of VRK1 in cellular processes such as DNA damage response, cell cycle regulation, and apoptosis. Researchers employ UNC3230 to investigate the therapeutic potential of VRK1 inhibition in cancer treatment, as VRK1 is often overexpressed in various malignancies. Additionally, it aids in understanding the molecular mechanisms underlying diseases where VRK1 plays a critical role, providing insights for developing targeted therapies.